{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:01:11Z","timestamp":1784721671533,"version":"3.55.0"},"reference-count":110,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":202,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Breast Cancer"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Triple\u2010negative breast cancer (TNBC) is a biologically diverse, highly aggressive class of breast cancer defined by the absence of estrogen, progesterone, and HER2 receptors. It accounts for approximately 10%\u201320% of all invasive breast cancers, and disproportionately affects women of younger ages and from minority groups. TNBC is distinguished by delayed diagnosis requiring special techniques, rapid metastatic progression, and limited treatment options compared with other breast cancers. Chemotherapy remains the mainstay but patients face higher relapse rates and overall survival is significantly reduced. TNBC represents a diverse array of subtypes, whose molecular differences impact their pathological behavior and response to therapy. Newer molecular markers in various stages of clinical and preclinical development show promise towards improving the management of TNBC patients. Membrane receptor proteins like trop2, nectin\u20104, LIV\u20101, gpNMB, CXCR4, DDR1, and PD\u2010L1 have been targeted with antibody\u2013drug complexes. Synthetic small molecules and antisense oligonucleotides have been employed for inhibition of internal cellular components like PARP enzyme and expression of genes related to cancer progression. The molecular makeup of the tumor microenvironment is also a significant factor in addressing TNBC metastasis. In conclusion, the stratification of TNBC patients on their molecular subtype needs to be more widely adopted, and a calculated combination of current and emerging strategies is needed to effectively address TNBC in the clinic.<\/jats:p>","DOI":"10.1155\/ijbc\/8575520","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:04:20Z","timestamp":1784718260000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Overview of Emerging Trends in Targeted Therapy of Triple\u2010Negative Breast Cancer"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7932-5901","authenticated-orcid":false,"given":"Anuj","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5895-7265","authenticated-orcid":false,"given":"Suresh","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"e_1_2_12_1_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3"},{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102672"},{"key":"e_1_2_12_3_2","volume-title":"Female Breast Cancer \u2014 Cancer Stat Facts","author":"National Cancer Institute","year":"2025"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.836417"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042420-093238"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S69488"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-025-01359-0"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230034"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040819"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00197-2"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0222"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0432"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2024.2333320"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38364-y"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000455820"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116584"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1244781"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07436-1"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.119442"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01262-8"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120321"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390464"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-GS5-01"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899423"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.09.004"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0038-2"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15060692"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01341-0"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00341-6"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i4.169"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00633-6"},{"key":"e_1_2_12_34_2","volume-title":"Phase 2, Open Label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in Patients With Advanced and\/ or Unresectable Non-Small Cell Lung Cancer (NSCLC), With Biomarker Analysis to Characterize Response to Therapy","author":"Roussy G.","year":"2025"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174516"},{"key":"e_1_2_12_36_2","volume-title":"An Open-Label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","author":"Astellas Pharma Global Development, Inc","year":"2025"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1354543"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw678"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00200"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01444-3"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266830"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268387"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91588-3"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00244-6"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051589"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00778-y"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06704-y"},{"key":"e_1_2_12_48_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2023.5283"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2024.2386621"},{"key":"e_1_2_12_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2023.08.003"},{"key":"e_1_2_12_51_2","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2022_220316N289"},{"key":"e_1_2_12_52_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006720"},{"key":"e_1_2_12_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.101100"},{"key":"e_1_2_12_54_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.808625"},{"key":"e_1_2_12_55_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051238"},{"key":"e_1_2_12_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_2_12_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.106019"},{"key":"e_1_2_12_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30689-8"},{"key":"e_1_2_12_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_2_12_60_2","volume-title":"FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-Mutated Non-Small Cell Lung Cancer","author":"Research C for DE","year":"2025"},{"key":"e_1_2_12_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz192"},{"key":"e_1_2_12_62_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.769280"},{"key":"e_1_2_12_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03227-6"},{"key":"e_1_2_12_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03844-x"},{"key":"e_1_2_12_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29552"},{"key":"e_1_2_12_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109978"},{"key":"e_1_2_12_67_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0491"},{"key":"e_1_2_12_68_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S225376"},{"key":"e_1_2_12_69_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2727.163129"},{"key":"e_1_2_12_70_2","doi-asserted-by":"publisher","DOI":"10.30699\/ijp.2025.2042447.3363"},{"key":"e_1_2_12_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0255"},{"key":"e_1_2_12_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30950-z"},{"key":"e_1_2_12_73_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3110"},{"key":"e_1_2_12_74_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2026.1714597"},{"key":"e_1_2_12_75_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes9010029"},{"key":"e_1_2_12_76_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101694"},{"key":"e_1_2_12_77_2","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering11080830"},{"key":"e_1_2_12_78_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1818"},{"key":"e_1_2_12_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2024.110585"},{"key":"e_1_2_12_80_2","volume-title":"Phase I Dose Finding Study of Selinexor and Tala zoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion 8 Cohort Study in Patients With Advanced\/ Metastatic Triple Negative Breast Cancers","author":"National University Hospital, Singapore","year":"2025"},{"key":"e_1_2_12_81_2","volume-title":"A Multicenter Single Arm Phase II Study With Bicalutamide in Combination With Abemaciclib in 4 Cohorts of Locoregionally Advanced Inoperable or Metastatic Androgen Receptor-Positive Triple-Negative Breast Cancer","author":"Universitaire Ziekenhuizen","year":"2025"},{"key":"e_1_2_12_82_2","volume-title":"ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)","author":"Wake Forest University Health Sciences","year":"2025"},{"key":"e_1_2_12_83_2","volume-title":"A Phase 3, Open-Label, Randomised Study of FDA018-ADC Versus Investigator\u2032s Choice of Chemotherapy in Patients Who Recurred During or After Taxane Therapy in Locally Advanced or Metastatic Triple-Negative Breast Cancer","author":"Fudan-Zhangjiang S.","year":"2026"},{"key":"e_1_2_12_84_2","unstructured":"Gilead Sciences A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician\u2032s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy Clinical Trial Registration. clinicaltrials.gov 2026."},{"key":"e_1_2_12_85_2","unstructured":"Gilead Sciences A Randomized Open-Label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician\u2032s Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1(Clinical trial registration. clinicaltrials.gov 2025)."},{"key":"e_1_2_12_86_2","unstructured":"SharpM.andDohmeL. L. C. A Phase 3 Randomized Open-Label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician\u2032s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (Tro Fuse-011)(Clinical trial registration. clinicaltrials.gov 2026)."},{"key":"e_1_2_12_87_2","volume-title":"A Single Arm, Phase II Study of Sacituzumab Tirumotecan (Sac-TMT) Combined With Toripalimab for First-Line Treatment of PD-L1 Positive Unresectable Locally Advanced\/ Metastatic Triple Negative Breast Cancer (a\/ mTNBC)","author":"Tianjin Medical University Cancer Institute and Hospital","year":"2025"},{"key":"e_1_2_12_88_2","volume-title":"Phase 1, Two-part, Multicenter, Open-Label, Multiple Dose, First-in-Human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-Pan Tumor 01)","author":"Daiichi Sankyo Co., Ltd","year":"2025"},{"key":"e_1_2_12_89_2","volume-title":"Precise Treatment for BLIS Subtype of Triple-Negative Breast Cancer in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer","author":"Shao Z.","year":"2024"},{"key":"e_1_2_12_90_2","volume-title":"A Phase 1a\/ 1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors","author":"Eli Lilly and Company","year":"2026"},{"key":"e_1_2_12_91_2","volume-title":"4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-Label, Single-Centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With Metastatic Breast Cancer","author":"Joshua A.","year":"2025"},{"key":"e_1_2_12_92_2","unstructured":"Memorial Sloan Kettering Cancer Center Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive\/ Her 2 Negative Breast Cancers\u2009: Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune Responses(Clinical trial registration. clinicaltrials.gov 2025)."},{"key":"e_1_2_12_93_2","volume-title":"A Phase Ib\/ II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer","author":"Biotheus Inc","year":"2025"},{"key":"e_1_2_12_94_2","volume-title":"A Multicenter, Randomized, Double-Blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-Line Treatment in Inoperable Locally Advanced\/ Metastatic Triple-negative Breast Cancer (TNBC)","author":"Biotheus Inc","year":"2025"},{"key":"e_1_2_12_95_2","unstructured":"ShaoZ. An Open Randomized Phase III Study of Everolimus With Investigator\u2032s Choice of Chemotherapy Versus Chemotherapy in The First-Line Treatment of Luminal Androgen Receptor (LAR) Subtype With PI3K\/ AKT \/ mTOR Pathway Mutation of Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (BCTOP-T-M03)(Clinical trial registration. clinicaltrials.gov 2024)."},{"key":"e_1_2_12_96_2","volume-title":"A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-Lineage Lymphoma Proto-Oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types","author":"Nurix Therapeutics, Inc","year":"2025"},{"key":"e_1_2_12_97_2","volume-title":"A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)","author":"Mittendorf E. A.","year":"2025"},{"key":"e_1_2_12_98_2","volume-title":"An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","author":"Therapeutics I.","year":"2026"},{"key":"e_1_2_12_99_2","volume-title":"An Open-Label, Multicenter, Phase 1\/ 1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies","author":"Therapeutics J.","year":"2025"},{"key":"e_1_2_12_100_2","unstructured":"Marengo Therapeutics Inc A Phase 1b\/ 2 Open-Label Study to Investigate the Safety and Efficacy of Invikafusp Alfa (STAR 0602) a Selective T Cell Receptor (TCR)-Targeting Bifunctional Antibody-Fusion Molecule in Combination With Sacituzumab Govitecan in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (START-002)(Clinical trial registration. clinicaltrials.gov 2025)."},{"key":"e_1_2_12_101_2","volume-title":"QL1706 Plus Nab-paclitaxel +\/ - Bevacizumab As 1L Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: A Non-Randomized, Multicenter Phase II Study","author":"Wang H.","year":"2025"},{"key":"e_1_2_12_102_2","volume-title":"Camrelizumab Combined With Liposomal Doxorubicin and Losartan in the Treatment With Advanced or Locally Advanced Triple-Negative Breast Cancer Who Have Received no More Than 1 Prior Line of Chemotherapy","author":"Zhao Y.","year":"2021"},{"key":"e_1_2_12_103_2","volume-title":"Randomized Phase II Trial Evaluating the Efficacy of Paclitaxel+Bevacizumab INDUCtion Followed by at at Ezolizumab+Nab-paclitaxel for PD-L1-positive Metastatic Triple Negative Breast Cancer (JBCRG-M10, CMA-0196) (INDUCE Trial)","author":"Japan Breast Cancer Research Group","year":"2025"},{"key":"e_1_2_12_104_2","volume-title":"Reverse Triple Negative Immune Resistant Breast Cancer","author":"Shao Z.","year":"2025"},{"key":"e_1_2_12_105_2","volume-title":"Single Arm, Open Label Phase 1b\/ 2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer","author":"Seagen Inc","year":"2025"},{"key":"e_1_2_12_106_2","volume-title":"A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI 4736) in Participants With Advanced Solid Tumours","author":"Zeneca A.","year":"2024"},{"key":"e_1_2_12_107_2","volume-title":"A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer","author":"Roche H.-L.","year":"2024"},{"key":"e_1_2_12_108_2","doi-asserted-by":"crossref","DOI":"10.1101\/2024.07.24.603752","volume-title":"Discovery and Evaluation of Novel Biomarkers Reveal Dasatinib as a Potential Treatment for a Specific Subtype of Triple-Negative Breast Cancer","author":"Ortega-\u00c1lvarez D.","year":"2024"},{"key":"e_1_2_12_109_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4717-y"},{"key":"e_1_2_12_110_2","doi-asserted-by":"publisher","DOI":"10.4274\/ejbh.galenos.2021.2021-3-4"}],"container-title":["International Journal of Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ijbc\/8575520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/ijbc\/8575520","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ijbc\/8575520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:04:33Z","timestamp":1784718273000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/ijbc\/8575520"}},"subtitle":[],"editor":[{"given":"V.","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/ijbc\/8575520"],"URL":"https:\/\/doi.org\/10.1155\/ijbc\/8575520","archive":["Portico"],"relation":{},"ISSN":["2090-3170","2090-3189"],"issn-type":[{"value":"2090-3170","type":"print"},{"value":"2090-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"8575520"}}